Infectio最新文献

{"title":"Guía de práctica clínica para la infección de vías urinarias complicada","authors":"Jorge Alberto Cortés, Nairo Cano Arenas, José Danilo Camero Blanco, Martha Carolina Valderrama-Ríos, Cándida Diaz Brochero, Wilfredo Donoso Donoso, Andrés Felipe Puentes Bernal, G. Esparza, Sonia Isabel Cuervo-Maldonado, Patricia Reyes Pabón, Catalina Torres-Espinosa, W. Chaves, Sugeich Del Mar Meléndez Rhenals, Kateir Contreras, F. Guevara, J. Bravo-Ojeda, Felipe García López","doi":"10.22354/24223794.1120","DOIUrl":"https://doi.org/10.22354/24223794.1120","url":null,"abstract":"La infección de vías urinarias complicada es la infección que ocurre en alguna de las estructuras del tracto urinario, en pacientes con comorbilidad, o con anomalías estructurales o funcionales del tracto urinario. La infección de vías urinarias complicada tiene un alto impacto en morbilidad, mortalidad y en la problemática actual de resistencia a los antimicrobianos, por lo que resulta de importancia generar directrices que permitan orientar el adecuado diagnóstico y tratamiento en este grupo de pacientes, con el objetivo de obtener mejores desenlaces clínicos y propender por un uso racional de antibióticos. La presente guía contiene recomendaciones para el diagnóstico y tratamiento de pacientes adultos con infección de vías urinarias complicada, basadas en la evidencia, realizadas mediante el proceso de adaptación de guías de práctica clínica para el contexto colombiano.","PeriodicalId":38132,"journal":{"name":"Infectio","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41785097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perfil epidemiológico de la infección por SARS-COV-2 en pediatría","authors":"Mario Bustos-Paz, Margarita Pedraza-Galvis, Silvia Acero-Azuero, Claudia Granados-Rugeles, Ana María Constain-Ramos, Melissa De Castro-Hernandez, Mercy Moncaris-Gonzalez, Diana Bejarano-Morales, Diana Bojacá-Chauta, Álvaro Cusba-Infante, Yudy Corredor-Becerra, A. Bertolotto-Cepeda, S. Restrepo-Gualteros, J. López-García, M. Rondón-Sepulveda","doi":"10.22354/24223794.1111","DOIUrl":"https://doi.org/10.22354/24223794.1111","url":null,"abstract":"Objetivo: Describir el perfil epidemiológico y clínico de los pacientes pediátricos que fueron atendidos por sospecha de infección de COVID-19, entre marzo y octubre del 2020, en el Hospital Universitario San Ignacio (HUSI), en Bogotá, Colombia. Materiales y métodos: Diseño de corte transversal. Descripción de los pacientes con edades comprendidas entre 1 mes de vida hasta 1 día antes de cumplir 18 años, valorados entre en marzo y octubre del 2020, que fueron abordados por cualquier servicio de atención pediátrica de un hospital universitario por sospecha de infección por COVID-19, según los protocolos nacionales e institucionales vigentes. Se registraron variables demográficas y el motivo de consulta de todos los individuos con sospecha de infección. Únicamente cuando se confirmó la infección por SARS-CoV-2 se registraron las variables relacionadas con aspectos clínicos de la enfermedad y su evolución. Resultados: Se evaluaron 920 registros médicos de pacientes pediátricos con sospecha de infección por SARS-CoV-2, de los cuales hubo 157 casos confirmados con infección por COVID-19. El principal motivo de consulta para sospechar infección fue fiebre en un 50% de los casos. En los pacientes con confirmación virológica el 32.48% de los casos atendidos requirieron manejo hospitalario. Se sospechó MIS-C en 5 pacientes que requirieron manejo en unidad de cuidados intensivos. En el lapso evaluado no hubo fallecimientos asociados a la infección por COVID-19. Conclusiones: La infección por SARS-CoV-2 se relaciona en la mayoría de los casos con un espectro de enfermedad leve en la población pediátrica. Este estudio sugiere que podrían ser mayores los pacientes pediátricos que debutan con síntomas gastrointestinales que respiratorios, y que la frecuencia de complicaciones renales debe ser tenida en cuenta en los pacientes en quienes se sospecha el síndrome inflamatorio sistémico asociado al COVID-19.","PeriodicalId":38132,"journal":{"name":"Infectio","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48736641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Female scientists in infectious diseases field: working towards a better representation and inclusión","authors":"M. D. Correa, Lucy Gabriela Delgado, M. Francia, P. Jokelainen, Claudia Saavedra, Leidy L. García, J. Gómez‐Marín","doi":"10.22354/24223794.1109","DOIUrl":"https://doi.org/10.22354/24223794.1109","url":null,"abstract":"","PeriodicalId":38132,"journal":{"name":"Infectio","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47467177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical efficacy and safety of ivermectin (400 ug/kg, single dose) in patients with severe COVID-19: a randomized clinical trial","authors":"F. Ochoa-Jaramillo, Federico Rodríguez-Vega, N. Cardona-Castro, Verónica Posada-Vélez, D. Rojas-Gualdrón, Heidy Contreras-Martínez, A. Romero-Millan, Jessica Porras-Mansilla","doi":"10.22354/24223794.1105","DOIUrl":"https://doi.org/10.22354/24223794.1105","url":null,"abstract":"Purpose: To evaluate the clinical efficacy of including Ivermectin (single dose on day 1 of 400 ug/kg PO) in the standard of care in hospitalized adults with severe COVID-19. Methods: Double-blinded, parallel, placebo-controlled, single-center, randomized clinical trial. Seventy-five patients were randomly assigned (1:1) to receive standard of care plus ivermectin or placebo and were followed up for 21 days. Primary outcome measure was admission to ICU and secondary outcomes were the requirement of intensive mechanical ventilation (IMV) and in-hospital death. Intention-to-treat analyses, estimated risk differences (RD), and Hazard ratios (HR) with Cox regression were performed. Results: Enrollment stopped due to the lack of eligible patients. Thirty-seven patients were assigned to intervention and 38 to placebo. Patients in the ivermectin group were 54.5 years on average, 62.2% were male. Comorbidities were more prevalent in the control group (78.9% vs. 56.8%). There was no difference in the 21-day risk of admission to the ICU between ivermectin (21.6%) and placebo (15.8%) (RD= 5.8%; 95%CI: -11.8%-23.5%); neither in the risk of requirement of IMV (18.9% vs 13.2%), mortality (5.4% vs 10.5%) or in adverse events (32.4% vs. 28.9%). Discussion: Ivermectin showed no significant benefit in reducing the requirement of ICU, IMV, or mortality for severe COVID-19 patients.","PeriodicalId":38132,"journal":{"name":"Infectio","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46328956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances and Challenges in COVID-19 Vaccination in Latin American: A public health perspective","authors":"Daniel Fernández-Guzmán, Edward Chávez-Cruzado, C. Díaz-Vélez, T. Gálvez-Olortegui, Esteban Vergara-de la Rosa, A. Rodríguez-Morales, J. Galvez-Olortegui","doi":"10.22354/24223794.1094","DOIUrl":"https://doi.org/10.22354/24223794.1094","url":null,"abstract":"The vaccination against SARS-CoV-2 has been recognized as a priority strategy to safeguard public health. However, disparities in productive, acquisitive and distributional capacity have led to delays in immunization, particularly in low- and middle-income countries. Consequently, global coverage is expected to achieve herd immunity against COVID-19 by 2023 or 2024, although with highly variable coverage percentages among countries. In Latin America, immunization against COVID-19 faces different challenges to achieve herd immunity. To date (February 6, 2022), the countries that had several doses needed to immunize their populations with at least two doses (number of doses between population) were Peru (520.7%), Chile (458.4%), Argentina (298.0%), Brazil (236.6%), Bolivia (206.0%) and Uruguay (unconfirmed doses). On the other hand, Uruguay (210.7%) and Chile (238.3%) have applied twice as many doses as their populations. Argentina (194.3%), Brazil (173.6%), Ecuador (170.3%), Peru (170.3%), Costa Rica (161.1%), and Panama (153.5%) are on the way to achieving this goal. In addition, Latin American countries also showed an insufficient distribution of vaccines and a storage capacity limited to only a few cities and multiple frequencies of vaccine hesitancy. Due to these scenarios, the production of more vaccine doses and equitable distribution to the rest of the population within the Latin American region should remain a public health priority to achieve collective immunity in the shortest time possible","PeriodicalId":38132,"journal":{"name":"Infectio","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45625498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cat-scratch disease, ¿does it always present with lymphadenopathy?: A case report","authors":"Diego Urbano-Pulido, Mayra Quintero-Palacios, J. López-Cubillos, G. Camacho-Moreno","doi":"10.22354/24223794.1096","DOIUrl":"https://doi.org/10.22354/24223794.1096","url":null,"abstract":"Cat-scratch disease (CSD) is a zoonotic disease, caused by Bartonella henselae, a gram-negative bacillus, that has a variable clinical presentation and must be suspected in immunocompetent patients or immunocompromised patients with prolonged febrile syndrome of unknown origin that have history of interaction with cats. Diagnosing CSD may be challenging, so clinical suspicion and a thorough clinical interview and workup are essential to come up with a definitive conclusion. Typically, CSD presents with regional lymphadenopathies and subsequent systemic compromise. However, it can present with a unique manifestation such as hepatosplenic compromise. Herein, we present a patient with prolonged febrile syndrome with systemic symptoms and reticuloendothelial compromise.","PeriodicalId":38132,"journal":{"name":"Infectio","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46183445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic evaluation of two enzyme-linked immunosorbent assay tests for Trypanosoma cruzi infection in a Colombian population","authors":"S. Suescún-Carrero, Ángela Liliana Monroy-Díaz, Philippe Ferdinand Tadger-Viloria, Carlos Ernesto Vargas-Niño, M. Medina-Alfonso, Laura Ximena Ramírez-López","doi":"10.22354/24223794.1082","DOIUrl":"https://doi.org/10.22354/24223794.1082","url":null,"abstract":"Objective: To evaluate the diagnostic accuracy of two enzyme-linked immunosorbent assay tests to determine Trypanosoma cruzi infection in a Colombian population. Material and methods: Analytical study with case-control design of a diagnostic evaluation. Sensitivity, specificity and diagnostic efficacy of total CHAGATEK ELISA and recombinant CHAGATEK ELISA were determined. Positive predictive value, negative predictive value, and positive and negative likelihood ratios were calculated. The kappa coefficient was found to estimate the concordance between the index and reference tests. The discriminatory capacity of the tests was expressed by the area under the ROC curve. Results: Of the 184 samples included in the study, 99 were negative for T. cruzi and 85 were positive according to the reference tests used. Sensitivity for total and recombinant ELISA was 97.6 % and 98.8 %, respectively; while specificity was 97.0% and 94.9%. The level of concordance of the total and recombinant ELISA was almost perfect and the discriminatory ability of the two tests were good. Conclusions: It was demonstrated that the two tests can confirm and exclude the diagnosis of Chagas disease and have a good diagnostic performance.","PeriodicalId":38132,"journal":{"name":"Infectio","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47948327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reacción similar a la enfermedad del suero secundaria al uso de cefalotina: reporte de un caso","authors":"Germán Sepúlveda-Barbosa, M. A. Montoya-Giraldo, Gabriel Restrepo-Chavarriaga, A. F. Zuluaga","doi":"10.22354/24223794.1099","DOIUrl":"https://doi.org/10.22354/24223794.1099","url":null,"abstract":"La enfermedad del suero (SS, por sus siglas en inglés) y las reacciones similares a la SS (SSLR) son entidades clínicas indistinguibles pero con procesos fisiopatológicos diferentes, particularmente respecto al impacto en el sistema del complemento. La base de datos VigiAccess™ sólo contiene 3 casos potenciales de SS entre 2890 registros para cefalotina reportados entre 1968 y diciembre de 2021, pero ninguno de SSLR. Este antibiótico de uso común fue aprobado en 1974, y sus primeros estudios clínicos describieron que la totalidad de voluntarios sanos podían producir SSLR dependiendo de la dosis y velocidad de infusión. Aquí presentamos el caso de una mujer joven, previamente sana, quien sufrió un accidente ofídico y se le administró antiveneno y cefalotina, tras lo cual desarrolló aparentemente SS, requiriendo re-hospitalización, pero debido a que no hubo consumo de complemento, y su recuperación fue total y sin complicaciones, se definió como una probable SSLR.","PeriodicalId":38132,"journal":{"name":"Infectio","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49121828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infección por SARS-COV-2 en trabajadores de la salud: análisis de riesgo epidemiológico en una institución de alta complejidad de Bogotá, Colombia, 2020","authors":"Milcíades Ibáñez-Pinilla, L. Murcia, Leonardo Briceño, Carlos Trillos, C. Ramírez, J. Daza, Ingrid Ballesteros, J. Sanchez, G. Rodríguez","doi":"10.22354/24223794.1090","DOIUrl":"https://doi.org/10.22354/24223794.1090","url":null,"abstract":"Objetivo: Determinar la incidencia de infección por SARS-CoV-2 y su asociación con las características sociodemográficas, clínicas y ocupacionales, en los trabajadores de la salud (TS) del área de riesgo COVID-19. Material y método: Estudio analítico longitudinal en una cohorte de TS del área “Zafiro” de pacientes con sospecha o diagnóstico confirmado de infección por SARS-CoV-2. La identificación de casos positivos de SARS-CoV-2 se realizó con la prueba de RT-PCR. Resultados: La cohorte fue de 114 TS, con un promedio de 35.3±7.4 años, con cargo de médico general (26.3%), auxiliar de enfermería (21.1%) y enfermera (19.3%). La tasa incidencia de SARS-CoV-2 (31.6%) y reinfección (1.8%) durante siete meses. Los factores conjuntamente asociados a SARS-CoV-2: cohabitación con personas con alto riesgo de contagio (HR=2.406,IC95%:1.225,4.726,p=0.011), el menor nivel educativo (HR=2.241,C95%:1.051,4,782,p=0.037) y un mayor consumo de medicamentos para dormir (HR=4.680, IC95%: 1.328,16.486, p=0.016). Conclusiones: La tasa de contagio de SARS-CoV-2 durante siete meses de la pandemia, en los trabajadores de la salud fue alta (uno de cada tres TS) asociada a cohabitación con personas de alto riesgo, menor nivel educativo y mayor consumo de medicamentos para dormir. Una situación de preocupación en los TS fueron los casos sospechosos de reinfección del SARS-CoV-2.","PeriodicalId":38132,"journal":{"name":"Infectio","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45007253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Síndrome de Miller-Fisher seguido por vacuna Sputnik V","authors":"Ángel Chacón-Pazmiño, Vicente P. Realpe-Pantoja, María C. Hernández-Obando, Gloria Delgado-Nacaza, María A. Unigarro-Tapia, J. D. Portillo-Miño","doi":"10.22354/24223794.1097","DOIUrl":"https://doi.org/10.22354/24223794.1097","url":null,"abstract":"El síndrome de Miller Fisher (SMF) definido como una variante rara del síndrome de Guillain-Barré (SGB), es caracterizado por la triada clásica de ataxia, arreflexia y oftalmoplegía. Es una polineuropatía desmielinizante resultado de una respuesta autoinmune desregulada secundaria a la infección por virus y bacterias. El SMF y SGB ha sido descrito durante la pandemia de COVID-19. Existen algunos reportes en la literatura de SGB después de la vacunación por COVID-19. En cambio, los reportes de SMF post-vacunación para SARS-COV-2 son escasos en la literatura. Se presenta paciente de 75 años de edad quien consulta por astenia, adinamia y dificultad para la deglución que progresa a dificultad respiratoria. Refiere como antecedente de importancia la aplicación de vacuna Sputnik V. Durante la estancia hospitalaria se diagnóstica mediante electromiografía más estudio de conducción nerviosa SGB variante SMF. El objetivo es exponer un SMF post-vacunación para SARS-CoV-2 con Sputnik V y resaltar la importancia de este antecedente para la vigilancia en la práctica clínica e investigaciones futuras.","PeriodicalId":38132,"journal":{"name":"Infectio","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41773516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}